Abstract 161P
Background
Chitinase 3-like 1 (CHI3L1) gene codes for the YKL-40 protein. Serum YKL-40 levels are controlled by polymorphisms in the proximal promoter region of CHI3L1 gene. Aim: We aimed to investigate the association of rs880633 (T/C) polymorphism at CHI3L1 gene with serum YKL-40 production and to evaluate the role of this polymorphism as a risk for HCC and its impact on patient’s survival.
Methods
225 subjects were classified into two groups, group I: included 120 HCC patients and group II: included 105 age & gender matched healthy volunteers. Genotyping of (T/C) polymorphism rs880633 at CHI3L1 gene was analyzed using allelic discrimination assay by Real-Time PCR technique and serum YKL-40 level was determined by ELISA.
Results
There was a significant statistical difference as regards genotype frequency of CHI3L1 gene T/C polymorphism between the two studied groups, with increased frequency of CC genotype among HCC patients and increased frequency of TT genotype among the control group. As regards allelic distribution, C allele was significantly more dominant in HCC patients that have increased HCC risk with odds ratio (CI = 95%) of 2.05(1.40 – 2.99) comparing to T allele. Subjects carrying CC genotype had the highest levels serum YKL40 followed by those with TC genotype, while subjects with TT genotype were found to have the lowest serum YKL40. HCC Patient with TT genotype had significantly longer survival rate than those had TC, CC genotypes, Overall survival of HCC patients revealed that both CC and CT genotypes had significantly shorter survival rate than those had TT genotype (P value <0.05).
Conclusions
CHI3L1 gene variants rs880633 might be a candidate risk factor for HCC. Carriers of CC genotype have highest serum YKL40 levels, are associated with criteria of bad prognosis. So, genotyping of (T/C) polymorphism rs880633 at CHI3L1 gene could predict the patient outcome.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Menoufia University.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
117P - Short-term and long-term outcomes of hepatectomy combined with intraoperative radiofrequency ablation for multiple colorectal liver metastases: A propensity score matching study
Presenter: Wenbai Huang
Session: Poster display session
Resources:
Abstract
119P - The impacts of dose-time-fractionation schedules on pathological complete response rate (pCR) and local recurrence (LR)
Presenter: Fu Jin
Session: Poster display session
Resources:
Abstract
120P - Platelet to lymphocyte ratio is associated with tumour localization and outcomes in patients with metastatic colorectal cancer
Presenter: Ahmet Bilici
Session: Poster display session
Resources:
Abstract
121P - Meta-analysis of three-dimensional versus two-dimensional laparoscopic surgery for rectal cancer
Presenter: Laiyuan Li
Session: Poster display session
Resources:
Abstract
127P - Outcomes based on albumin‐bilirubin (ALBI) grade in the phase III CELESTIAL trial of cabozantinib versus placebo in patients with advanced hepatocellular carcinoma (HCC)
Presenter: Stephen Chan
Session: Poster display session
Resources:
Abstract
128P - Tislelizumab in combination with chemotherapy for Chinese patients (Pts) with gastric/gastroesophageal junction cancer (GC/GEJC) or esophageal squamous cell carcinoma (ESCC)
Presenter: Yuxian Bai
Session: Poster display session
Resources:
Abstract
129P - Monitoring patient-specific mutation in ctDNA and CTC for tumour response evaluation after neoadjuvant chemotherapy in advanced gastric adenocarcinoma (NCT03425058)
Presenter: Tao Fu
Session: Poster display session
Resources:
Abstract
130P - Development of a liver cancer risk prediction model for the general population in china: A potential tool for screening
Presenter: Xiaoshuang Feng
Session: Poster display session
Resources:
Abstract
131P - Cabozantinib in Asian patients with hepatocellular carcinoma and other solid tumours: Population pharmacokinetics analysis
Presenter: Chih-Hung Hsu
Session: Poster display session
Resources:
Abstract
132P - Liposomal irinotecan (nal-IRI) plus 5-fluorouracil/levoleucovorin (5 FU/LV) vs 5-FU/LV in Japanese patients (pts) with gemcitabine-refractory metastatic pancreatic cancer (mPAC)
Presenter: Tatsuya Ioka
Session: Poster display session
Resources:
Abstract